Compare Diamondback Energy Inc (FANG) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Diamondback Energy Inc vs Mesoblast Limited — how do they compare? Diamondback Energy Inc trades at $200.69 (market cap $56.48B), while Mesoblast Limited trades at $16.86 (market cap $2.21B). The key difference: Diamondback Energy Inc is far larger — about 25.6× Mesoblast Limited's market cap, and Diamondback Energy Inc pays a 2.18% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| FANG | MESO | |
|---|---|---|
Market Cap | $56.48B | $2.21B |
Sector | Energy | Technology |
52-Week High | $213.69 | $20.96 |
52-Week Low | $134.53 | $12.88 |
Enterprise Value | $68.63B | $2.21B |
Dividend Yield | 2.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Diamondback Energy (FANG) trades at $200.97, up 1.01% with strong bullish technical signals and positive earnings momentum. The company delivered Q2 2026 EPS of $6.48, beating estimates by 6.6%, while revenue growth accelerated to $14.93B in 2025. Analyst consensus remains overwhelmingly bullish with 90% buy ratings and a $236.63 price target, representing 18% upside potential. Recent news highlights operational excellence and production growth guidance increases.
The outlook remains positive with production growth and debt reduction supporting valuation expansion. Key risks include oil price volatility and execution challenges amid global supply disruptions. Institutional interest remains strong with recent positions from Balefire LLC, though some trimming occurred from Bank of Nova Scotia. The combination of earnings beats, improved guidance, and favorable technicals suggests continued upward momentum.
MESO trades at $16.9, up 1.32% on the day, with a bullish technical signal from moving averages. The company reported Ryoncil net revenues of $36 million for the quarter ended June 30, 2026, and achieved its target of 300 patients in a Phase 3 trial for chronic low back pain. Despite strong revenue growth from its commercial launch, fundamentals show a net income margin of -144.33% and negative EBITDA of $80.06 million for 2025, reflecting significant losses amid expansion.
The outlook hinges on commercial execution and regulatory progress, with analyst consensus leaning buy (45% buy ratings). Key risks include high cash burn, dependence on pipeline success, and competitive pressures. Upside potential exists if revenue growth accelerates and losses narrow, but investors face volatility from clinical trial outcomes and funding needs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Diamondback Energy Inc
Diamondback Energy is an independent oil and gas producer in the United States. The company operates exclusively in the Permian Basin. At the end of 2021, the company reported net proven reserves of 1.8 billion barrels of oil equivalent. Net production averaged about 375,000 barrels per day in 2021, at a ratio of 60% oil, 20% natural gas liquids, and 20% natural gas.
Read more on FANG →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
